Rare disease focus Leverage Pharming Group's specialization in rare, debilitating, and life-threatening diseases to position high-value, targeted therapies and companion diagnostics partnerships with patient advocacy groups and specialty distributors.

Joenja growth capitalize on Joenja's continued growth while RUCONEST declines, offering lifecycle management opportunities, clinical expansion collaborations, and strategic manufacturing/co-promotion discussions with global partners.

Global footprint Target cross-border commercialization and EU-US market access opportunities, including partnerships with OrphanPacific for Japan, to broaden distribution, regulatory support, and synchronized supply chains.

Strategic partnerships Propose collaboration, licensing, or co-development deals with pharma players seeking a diversified biopharma portfolio and complementary small molecule and biologics capabilities.

Investor and events momentum Utilize active investor engagement and conference participation to schedule meetings with potential acquirers, tier-one distributors, and PE/VC groups focused on rare disease and specialty therapeutics.